Long-Term Clinical and Hemodynamic Outcomes after Heart Transplantation in Patients Pre-Treated with Sildenafil by Sofia Lázaro Mendes (7888673)

“…Results After treatment with sildenafil but before HT, PVR (-39%) and sPAP (-10%) decreased significantly. sPAP decreased after HT in both groups, but it remained significantly higher in group A vs. group B (40.3 ± 8.0 mmHg vs 36.5 ± 11.5 mmHg, p=0.022). …”

Absolute values of <i>M</i>₁ and <i>M</i>₂. by Tobit Führes (12647099)

“…Seven healthy volunteers underwent diffusion-weighted magnetic resonance imaging (DWI) with five diffusion encoding schemes (monopolar, velocity-compensated (<i>M</i>₁ = 0), acceleration-compensated (<i>M</i>₁ = <i>M</i>₂ = 0), 84%-<i>M</i>₁–<i>M</i>₂-compensated, 67%-<i>M</i>₁–<i>M</i>₂-compensated) at b-values of 50 and 800 s/mm² at a constant echo time of 70 ms. …”

Liver azoxystrobin residues after 1 and 2 months treatment with different doses of azoxystrobin on male rats. by Ekramy Halawa (11785086)

Death probability (%) of newly developed branches of persimmons according to the densities of <i>P</i>. <i>shantungensis</i> egg masses. by Sunghoon Baek (7042535)

Data Sheet 7_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 6_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 1_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 3_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 8_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 4_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 5_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 2_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Contribution of GIRK2-containing channels to RMP and GABA_B-induced inhibition of NPY neurons. by Youjin Oh (3308670)

“…(E) Small hyperpolarizing current steps (from −50 pA to 0 pA by 10 pA increments) were applied before (control) and after (baclofen) applications of baclofen. …”

Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate by Jairo E. Perez-Franco (3166050)

“…<i>braziliensis</i> (95.4%) and 35% of the parasites isolated showed a significant decrease in <i>in vitro</i> Glucanatime susceptibility associated with previous administration of the medicament. …”

Effects of busulfan treatment on CX43 and N-Cadherin. by Lingjun Zhao (21763122)

“…<p>The gap junction protein CX43 (A) and the ectoplasmic specialization-related protein N-Cadherin (B) were detected by immunofluorescence assay. …”

Comparing encoding efficiency of odorants’ correlation. by Mario Pannunzi (553941)

Encoding concentration ratio with average PN activity. by Mario Pannunzi (553941)

Responses to synchronous pulses of the control, LN, mix and NSI model. by Mario Pannunzi (553941)

Comparing encoding efficiency of odorants’ correlation, similar results of Fig 10 using threshold 150 Hz. by Mario Pannunzi (553941)

Figure S5 Two serotonin receptors, SER-1 and SER-7, act redundantly to suppress the Dar phenotype. by Rachel Mcmullan (506214)

“…Unlike wild type animals, this clearance rate was not altered by treatment with exogenous 5-HT (C).</p>…”